<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943318</url>
  </required_header>
  <id_info>
    <org_study_id>BRM_LC_Cohort</org_study_id>
    <nct_id>NCT01943318</nct_id>
  </id_info>
  <brief_title>Boramae Hospital Liver Cirrhosis Patient Cohort Study</brief_title>
  <official_title>Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Boramae Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Boramae Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver cirrhosis represents a worldwide health problem and is a major cause of mortality.
      Cirrhosis is the common end for chronic alcohol abuse and hepatitis C and B virus infections.
      Patients who have cirrhosis have varying degrees of compensated liver function, and
      clinicians need to differentiate between those who have stable, compensated cirrhosis and
      those who have decompensated cirrhosis. It is shown various complications: portal
      hypertension, hepatocellular carcinoma, hepato-renal syndrome, etc.

      Thus, it is important to have this information to manage disease and determine specific
      therapy. However, register-based studies in have not been reported in Korea.

      The goal of this study is to describe the natural history of a large number of patients with
      liver cirrhosis prospectively followed, and to identify predictors of the occurrence of
      Hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are planning to recruit patients with liver cirrhosis, and collect the
      baseline clinical laboratory data. Biological tests, endoscopy,liver ultrasonography
      (including ARFI) and hepatic venous pressure gradient measurements will be performed if not
      done within 90 days prior to inclusion. During this visit, 20 ml of blood will be collected
      for freezing and storage of serum and plasma, and constitution of a DNA library.

      Monitoring: Patients will have regular surveillance with blood test, liver ultrasonography
      and medical consultation at least every 6 months, periodic assessment of esophageal, gastric
      varices and portal hypertensive gastropathy (every 1 year) and prevention of their rupture if
      any. An additional blood sampling of 20 ml will be taken at baseline and every year in order
      to perform whole blood, serum, plasma, peripheral blood mononuclear cells and DNA libraries;
      Data will be standardized and centralized in a single database.

      And alcoholic liver cirrhosis patients will undergo liver biopsy for polymerase chain
      reaction, western blot, immunohistochemistry and RNA analysis.

      After measurement of hepatic venous pressure gradient and liver stiffness at baseline a
      non-selective beta-blocker (NSBB,carvedilol) was initiated and increased stepwise (weekly)
      until the systolic blood pressure remained at&gt;100 mmHg and the heart rate was not &lt;60. The
      maximum target dose for carvedilol 25 mg/day. The hepatic venous pressure gradient response
      to NSBB was again assessed 6 weeks after the intake of carvedilol. A hemodynamic response to
      NSBB treatment was defined as a reduction in hepatic venous pressure gradient &gt;=20% compared
      to baseline or to an absolute value &lt;=12 mmHg. Compliance with therapy was monitored by
      monitoring of heart rate and blood pressure during clinical visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Liver-related outcome: Decompensated liver cirrhosis (ascites, variceal bleeding, hepatic encepahlopathy), occurence of hepatocellular carcinoma</measure>
    <time_frame>5 years</time_frame>
    <description>Cumulative incidence within 5 years Laboratory Tests: Albumin, Total bilirubin, prothrombin time, Platelet Hepatic venous pressure gradient measurement Imaging study like Liver CT or Liver ultrasonography Endoscopy for varix evaluation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>5 years</time_frame>
    <description>overall mortality - whatever the cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver-related mortality</measure>
    <time_frame>5 years</time_frame>
    <description>cumulative incidence of liver-related deaths</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <description>Alcoholic Liver Cirrhosis
Participants will undergo liver biopsy. Participants will undergo hepatic venous pressure gradient measurement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <description>Hepatitis B virus (HBV) Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <description>Hepatitis C virus (HCV) Liver Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune</arm_group_label>
    <description>Autoimmune Cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biliary</arm_group_label>
    <description>Primary or secondary biliary cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toxic</arm_group_label>
    <description>Medication related cirrhosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Others</arm_group_label>
    <description>Hepatic venous pressure gradient (HVPG) measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver biopsy</intervention_name>
    <description>Histologic evaluation</description>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <arm_group_label>Autoimmune</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Toxic</arm_group_label>
    <arm_group_label>Others</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hepatic venous pressure gradient (HVPG) measurement</intervention_name>
    <description>Hepatic venous pressure gradient (HVPG) measurement</description>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>Hepatitis B virus</arm_group_label>
    <arm_group_label>Hepatitis C virus</arm_group_label>
    <arm_group_label>Autoimmune</arm_group_label>
    <arm_group_label>Biliary</arm_group_label>
    <arm_group_label>Toxic</arm_group_label>
    <arm_group_label>Others</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      At enrollement, 20 ml of blood will be collected for freezing and storage of serum and
      plasma, and constitution of a DNA library
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Seoul National University Boramae hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥19years old Proven cirrhosis

          -  No previous hepatocellular carcinoma (treated or not)

          -  Signed informed consent

        Exclusion Criteria:

          -  serious associated short-term life threatening disease (except associated HIV viral
             infection and the liver disease itself)

          -  liver focal lesion suggestive of hepatocellular carcinoma

          -  patient under guardianship

          -  pregnant women

          -  inability to regular monitoring, for whatever reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Won Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boramae Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sae Kyung Joo, MD</last_name>
    <phone>821089619285</phone>
    <email>joo.sammy@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SNU-SMG Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sae Kyung Joo, MD.</last_name>
      <phone>821089619285</phone>
      <email>joo.sammy@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2012 Jun;47(6):702-9. doi: 10.3109/00365521.2012.661759. Epub 2012 Mar 19.</citation>
    <PMID>22428859</PMID>
  </reference>
  <reference>
    <citation>Reiberger T, Ferlitsch A, Payer BA, Pinter M, Homoncik M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Non-selective Î²-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol. 2012 May;47(5):561-8. doi: 10.1007/s00535-011-0517-4. Epub 2011 Dec 15.</citation>
    <PMID>22170417</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2013</study_first_submitted>
  <study_first_submitted_qc>September 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2013</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Boramae Hospital</investigator_affiliation>
    <investigator_full_name>Won Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Liver Cirrhosis</keyword>
  <keyword>Hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

